How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Pharmaceutical

Opportunities and Challenges for Cell and Gene ...

Gene therapy is an innovative medical approach that manipulates an individual’s genetic material to prevent or treat diseases. It primarily involves introducing, modifying, or substituting genes wi...

Feb 05, 2024

mrna-based-vaccines-and-therapeutics
Unleashing the Power of mRNA: A Revolutionary Approach to Vaccines and Therapeutics

The progress of mRNA-based therapeutics involves several key stages, including mRNA design, synthesis, entrapment, pharmacodynamics, pharmacokinetics, in vivo and in vitro safety evaluation, manufacturing, and clinical trials. Among these stages, mRNA design and synthesis play pivotal roles in developing mRNA-based...

Find More
Pharma News for Merck, BMS, Sanofi, Juvena
Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors

Merck’s KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Cancer (RCC) at an Increased Risk of Recurrence Following Nephrectomy Merck, also known as MSD beyond the United States and Canada, has revealed findings from the Phase III KEYNOTE-564 trial, which a...

Find More
ascvd-treatment-beyond-statin
Atherosclerotic Cardiovascular Disease (ASCVD) Treatment Approaches: Beyond Statins

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide, encompassing conditions such as coronary artery disease and stroke. The growing occurrence of ASCVD, fueled by elevated risk factors, cardiovascular disease, and diabetes, is contributing to an expanding market f...

Find More

More Views & Analysis

voydeya-for-pnh-treatment
AstraZeneca Strengthens Presence in PNH Treatment with Voydeya in Japan: World’s First Approval

A month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval fr...

Find More

Pharma News for Exelixis, AstraZeneca, Kyverna
BMS, and Exelixis’s Opdivo + CABOMETYX in First-Line Advanced Renal Cell Carcinoma; AIRSUPRA Now Available as the First and Only FDA-approved Anti-inflammatory Rescue Option for Asthma; AstraZeneca’s Voydeya Receives First-ever Regulatory Approval; EMA Grants ODD to GC Biopharma’s Sanfilippo Syndrome (Type A) Treatment; FDA Approves NRx Pharma’s IND Application of NRX-101; FDA Fast Track Designation to Kyverna’s KYV-101

Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investiga...

Find More

emerging-therapies-for-achondroplasia-treatment
Achondroplasia Treatment Space: Hunt for Potential Curative Therapies

Achondroplasia is a rare genetic disorder affecting bone growth, causing significant short stature, known as dwarfism. This condition is attributed to a fibroblast growth factor receptor 3 (FGFR3) gene mutation. The mutation results in an overactive FGFR3 gene, leading to a slowdown in bone formation within the car...

Find More

novel-drug-classes-for-nash-treatment
Game-Changers in Non-Alcoholic Steatohepatitis (NASH) Treatment: Insights into Novel Drug Classes

Non-alcoholic steatohepatitis (NASH) has emerged as a global health concern, affecting millions of individuals worldwide. NASH is a progressive liver disease characterized by inflammation and liver cell damage, often resulting from the accumulation of fat in the liver. According to DelveInsight’s evaluation in 2022...

Find More

A Glance at Key Insights From 42nd J.P. Morgan Annual Healthcare Conclave

From January 8th to 11th, 2024, the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) took center stage in San Francisco, CA, USA. Spanning four dynamic days, this conference saw the active participation of prominent figures from major pharmaceutical, biotechnology, Medtech, HealthTech entities, and emerging fa...

Find More

Pharma News for AskBio, Merck, SELLAS, RemeGen
Bayer’s AskBio Initiates Phase II GenePHIT Trial; FDA Approves Merck’s KEYTRUDA Plus Chemoradiotherapy as Treatment for Stage III-IVA Cervical Cancer; FDA Fast Track Designation to SELLAS Life Sciences R/R AML; RemeGen’s RC88; Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer; Tonix Pharma’s TNX-102 SL for Fibromyalgia

Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure Merck, also recognized as MSD in regions beyond the United States and Canada, has officially announced that the FDA has approved for the use of KEYTRUDA, Merck's anti-PD-1 therapy, in conjunction with chemoradiotherapy (CRT) for treatin...

Find More

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hyperten.....

Find More

Scleroderma is a chronic disease that affects the skin, the connective tissue that supports and hold.....

Find More

Herpes zoster oticus (HZ oticus) is a viral infection of the inner, middle, and external ear. A resu.....

Find More

AAV Vectors are the leading viral vectors for gene delivery to treat a variety of human diseases. Ad.....

Find More

Diabetic retinopathy is an eye condition that leads to vision loss and blindness in people who have .....

Find More

Atrial fibrillation market is brimming with novel therapies in different stages of clinical developm.....

Find More